Released Aug 5, 2026, before the open
10-Q filed Aug 5, 2026, 36 days after period end · 0000059478-26-000081
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2026 and provided updated 2026 financial guidance.
The release| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $22.97B | $15.56B | $11.30B | $8.31B |
| Net Income | $7.10B | $5.66B | $2.97B |
Eli Lilly & Co · CIK 59478 · Engraved from SEC EDGAR
| $1.76B |
| EPS Diluted | $7.94 | $6.29 | $3.28 | $1.95 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, and reported EPS of $7.94, up 26%, compared with Q2 2025.¶2¶3
Lilly raised 2026 full-year revenue guidance to $85.0 billion to $87.0 billion and updated full-year EPS guidance to $35.50 to $36.50.¶4
Q2 2026 worldwide revenue increased 48% to $23.0 billion, driven by a 60% increase in volume and partially offset by a 13% decrease in realized prices.¶5
Gross margin increased 50% to $19.7 billion, and gross margin as a percent of revenue was 85.8%, up 1.5 percentage points versus the same quarter last year.¶6